Omega Therapeutics to Present New Preclinical Data on Epigenomic Upregulation at the American Society of Gene and Cell Therapy 27th Annual Meeting
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) — Omega Therapeutics, Inc. (Nasdaq:OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place in Baltimore, MD, May 7 – 11, 2024. The poster will feature new preclinical data that demonstrate the ability of Omega’s programmable epigenomic controllers (ECs) to pre-transcriptionally upregulate gene expression across a diverse set of genes, offering a broad range of potential therapeutic applications.